What happened Shares of Rite Aid (NYSE: RAD) fell 20% Thursday after the drugstore chain cut its full-year financial outlook. So what Coronavirus-related social distancing measures have weighed on Rite Aid's revenue and profits. "During the fourth quarter our industry was impacted by a historically soft cough, cold, and flu season, as well as the continued impacts of COVID on the deferral of elective procedures and related acute prescription volume," CEO Heyward Donigan said in a press release. Rite Aid's stock price fell hard Thursday. Image source: Getty Images. Rite Aid's same-store sales declined roughly 5.6% in the fourth quarter, driven by a 37% plunge in cough, cold, and flu-related products. The sharp decline in these typically higher-margin sales, combined with higher COVID-related costs, dented the drugstore company's profitability. Rite Aid now expects to generate a net loss of as much as $100 million in fiscal 2021. Management also cut its forecast for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to between $425 million and $435 million, down from a prior estimate of $490 million to $520 million. Now what Donigan said prescription volume has returned to positive levels in March. Rite Aid is also administering COVID-19 vaccines in more than 1,800 of its locations, which should help to boost in-store traffic. Investors can expect to receive an update on Rite Aid's turnaround progress when it reports its fourth-quarter results on April 15. 10 stocks we like better than Rite AidWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Rite Aid wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source